Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari Sells 10,319 Shares

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, June 9th. The shares were sold at an average price of $30.38, for a total transaction of $313,491.22. Following the completion of the transaction, the chief operating officer now owns 72,363 shares in the company, valued at approximately $2,198,387.94. This represents a 12.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Eben Tessari also recently made the following trade(s):

• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $30.51, for a total transaction of $1,374,231.42.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $30.46, for a total transaction of $472,312.76.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $26.41, for a total transaction of $316,920.00.
• On Monday, April 14th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $20.48, for a total transaction of $245,760.00.

Kiniksa Pharmaceuticals Trading Up 2.1%

Shares of Kiniksa Pharmaceuticals stock traded up $0.57 on Friday, reaching $28.30. 907,293 shares of the stock were exchanged, compared to its average volume of 516,217. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $17.38 and a 1-year high of $30.69. The business has a fifty day moving average price of $25.12 and a two-hundred day moving average price of $22.17. The firm has a market capitalization of $2.07 billion, a PE ratio of -202.13 and a beta of 0.06.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. During the same period in the prior year, the business posted ($0.25) earnings per share. The firm's revenue for the quarter was up 72.5% compared to the same quarter last year. Research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. Peregrine Capital Management LLC grew its position in Kiniksa Pharmaceuticals by 1.8% during the fourth quarter. Peregrine Capital Management LLC now owns 244,043 shares of the company's stock worth $4,827,000 after buying an additional 4,361 shares during the period. New York State Common Retirement Fund grew its position in Kiniksa Pharmaceuticals by 12.4% during the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock worth $302,000 after buying an additional 1,680 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Kiniksa Pharmaceuticals during the fourth quarter worth about $258,000. Bank of New York Mellon Corp grew its position in Kiniksa Pharmaceuticals by 33.1% during the fourth quarter. Bank of New York Mellon Corp now owns 122,051 shares of the company's stock worth $2,414,000 after buying an additional 30,382 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Kiniksa Pharmaceuticals by 36.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock valued at $2,414,000 after purchasing an additional 32,393 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

KNSA has been the topic of a number of recent analyst reports. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Jefferies Financial Group boosted their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Wedbush reiterated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Finally, Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $38.80.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.